Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond

Bibliography

• GLICKMAN RM. Inflammatory bowel disease: In: Harrison's principles of internal medicine. Fauci AS, Braunwald E, Isselbacher KJ et al., (Eds), McGraw Hill, New York, USA (1998):1633–1645.
   Google Scholar
• MC QUAID KR: Alimentary tract. In: Current medical diagnosis and treatment. Tierney Jr LM, McPhee SJ, Papadakis MA (Eds), McGraw Hill, New York, USA (2002):571–673.
   Google Scholar
• SANDS BE: Therapy of inflammatory bowel disease. Gastroenterology (2000) 118:S68–S82.
   PubMed Web of Science ®Google Scholar
• •A good review article.
   Google Scholar
• TRAVIS S: Recent advances in immunomodulation in the treatment of inflammatory bowel disease. Ear: Gastroenterol. Hepatol (2003) 15:205–208.
   PubMedGoogle Scholar
• ••Very recent advances are covered in thisarticle.
   Google Scholar
• TUVLIN JS, KANE SV: Novel therapies in the treatment of ulcerative colitis. Expert Opin. Investig. Drugs (2003) 12:483–90.
   PubMedGoogle Scholar
• •Supplements the knowledge of the previous article.
   Google Scholar
• SOUTH JC, MADNEZ E, RACA M et al: Prothrombotic state and signs of endothelial lesion in patients with inflammatory bowel disease. Dig. Dis. Sri. (1995) 40:1883–1889.
   PubMedGoogle Scholar
• LIEBMAN HA, KASHANI N, SUTHERLAND D et al.: The Factor V Leiden mutation increases the risk of various thrombosis in patients with inflammatory bowel disease. Gastroenterology (1998) 115:830–834.
   PubMed Web of Science ®Google Scholar
• HELLO T, WARTIVAARA U, HALME L et al.: Arg506Gin Factor V mutation and val34Leu Factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand. Gastroenterol (1999) 330:170–174.
   Google Scholar
• VECCHI M, SACCHI E, SAIBENI S et al.: Inflammatory bowel diseases are not associated with major hereditary conditionspredisposing to thrombosis. DV. Dis. Sri.(2000) 45:1465–1469.
   PubMed Web of Science ®Google Scholar
• DAY R, FORBES A: Heparin, cell adhesion and pathogenesis of inflammatory bowel disease. Lancet (1999) 354:62–65.
   PubMed Web of Science ®Google Scholar
• KAM A, BORDA I, INWOOD M et al: Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology (1975) 68:245–251.
   PubMedGoogle Scholar
• GAFFNEY PR, DOYLE CT, GAFFNEY A et al.: Paradoxical response to heparin in 10 patients with ulcerative colitis. Am.,/ Gastroenterol (1995) 90:220–223.
   PubMed Web of Science ®Google Scholar
• ZAVGORODNIY LG, MUSTYATS AP: The use of anticoagulants in combined therapy of non-specific ulcerative colitis. Klin. Med. (Moskva) (1982) 60:74–80.
   Google Scholar
• •One of the earliest reports of the role of anticoagulants in UC.
   Google Scholar
• ZAHERNAKOVA TV,KASHMENSKAYA NA, MALTSEVA IV et al.: Hemostasis and heparin therapy in non-specific ulcerative colitis. Soviet Med. (Moskva) (1984):110–113.
   Google Scholar
• LAM A, BORDA IT, INWOOD MJ et al: Coagulation studies in ulcerative colitis and
   Google Scholar
• ••Crohn's disease. Gastroenterology (1975) 68:245–251.
   Google Scholar
• KOENIGS KP, MCPHEDRAN P,SPIRO HM: Thrombosis in inflammatory bowel disease. J. Clin. Gastroenterol (1987) 9:627–631.
   PubMedGoogle Scholar
• DHILLON AP, AMBONY A, SIM R et al: Mucosal capillary thrombi in rectal biopsies.Histopathology (1992) 21:127–133.
   PubMed Web of Science ®Google Scholar
• PAPA A, DANESE S, GASBORINI Al: Review article: potential therapeutic applications and mechanisms of action of heparin inflammatory bowel disease.Aliment. Pharmacol Ther. (2000) 14:1403–1411.
   PubMedGoogle Scholar
• FOLWACZNY C: Coagulation system andinflammatory bowel disease:therapeutic and pathophysiological implications.Z Gastroenterol (2002) 40:991–998.
   PubMed Web of Science ®Google Scholar
• FOLWACZNY C,FRICKE H,SPANNAGL M et al.: Heparin for therapy of ulcerative colitis: Therapy of a concomitant phenomenon or indication of pathophysiology? Z Gastroenterol (1995) 33:723–724.
   Google Scholar
• NELSON RM, COCCONI 0, ROBERTS WG et al.: Heparinoligosaccharides bind C- and P-selectin and inhibit inflammation. Blood (1993) 82:3253–3258.
   Google Scholar
• SZABO S, KUSSTATSCGHER G, SAKOULAS G et al.: Growth factors: 'endogenous drugs: for ulcer healing. Scand. Gastroenterol (1995) 30(Suppl.):15–18.
   Google Scholar
• KAPLANSKI G, FABRIGOULE M, BOULAY V et al.: Thrombin induces endothelial Type II acativation in vitro IL-I and TNF-alpha-independent IL-8 secretion and E-selection expression. Immunol(1997) 158:5435–5441.
   Google Scholar
• NALDINI A, CARNEY DH, BOCCI V et al.: Thrombin enhances T cell proliferative responses and cytokine production. Cell. brimunol. (1993) 147:367–77.
   PubMed Web of Science ®Google Scholar
• WHITE B, ANG YS, MAHMUD N et al: Heparin and inflammatory bowel disease. Lancet (1999) 354:1122–1123.
   PubMedGoogle Scholar
• ••Gives a good overview of role of heparinin IBD.
   Google Scholar
• BRAZIER F, YZET T, BORUCHOWICZ Aet al. Treatment of ulcerative colitis with heparin. Gastroenterology (1996) 110:A872 (Abstract).
   Google Scholar
• EVANS RC, WONG VS, MORRIS Al et al: Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of
   Google Scholar
• cases. Aliment. Pharmacol Ther. (1997) 11:1037–1040.
   Google Scholar
• FOLWACZNY C, WIEBECKE B, LOESCHKE K: Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease. Am.,/Gastroenterol (1999) 94:1551–1555.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, ROBERT ME, BITTON A et al.: A multi-center randomized controlled trial of heparin for the treatment of ulcerative colitis.Gastroenterology (2000) 116:A752(Abstract).
   Google Scholar
• PANES J, ESTEVE M, CABRE E et al: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology (2000) 119:903–908.
   PubMed Web of Science ®Google Scholar
• ANG YS, MAHMUD N, WHITE B et al: Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment. Pharmacol Ther. (2000) 14:1015–1022.
   PubMed Web of Science ®Google Scholar
• TORKVIST L, THORLACIUS H, SJOQUIST U et al.: Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment. Pharmacol Ther.(1999) 13:1323–1328.
   PubMed Web of Science ®Google Scholar
• VRIJ AA, JONSEN JM,SCHOR EJ et al.: Low molecular weight heparin in steroid refractory ulcerative colitis; clinical outcome and influence on mucosal capillary thrombi.Scand. Gastroenterol (2002) (Suppl.)41–47.
   Google Scholar
• DOTAN I, ARBER N, SANTO M et al.: Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig. Dis. Sci. (2001) 46:2239–2244.
   PubMed Web of Science ®Google Scholar
• ••Gives a comprehensive insight into thepossible mechanisms of heparin action in IBD.
   Google Scholar
• Efficacy of low molecular weight heparins in ulcertative colitis. Abstract presented at: Digestive Disease Week, Orlando, USA, May 18 (2003).
   Google Scholar
• COHEN RD: Evolving medical therapies for ulcerative colitis. Curt Gastroenterol Rep. (2002) 4:497–505.
   PubMedGoogle Scholar
• WOLF JM, LASHNER BA: Inflammatory bowel disease: Sorting out the treatment options. Cleve. Clin. J. Med. (2002) 69:621–626.
   PubMed Web of Science ®Google Scholar
• JAFRI S, PASRICHA J: Agents used for diarrhea, constipation and inflammatory bowel disease: agents used for biliary andpancreatic disease. In: Goodman and GilmanS Pharmacological Bash of Therapeutics. Harlman JG, Limbird LE (Eds), McGraw Hill, New York, USA (2001) 1037:1037–1058.
   Google Scholar
• OKEMURA S, ARKI H, OHASHI S et al: Efficacy of cyclosporine with corticotrophin for refractory ulcerative colitis.Hepatogastroenterol (2003) 50:91–94.
   PubMedGoogle Scholar
• ARIDUS T, KLEBL F, ROGLER G et al Patients with refractory Crohn's disease or ulcerative colitis respond to dehydropiandrosterone: a pilot study.Aliment Pharmacol Ther. (2003) 17:409–414.
   PubMedGoogle Scholar
• GORNET JM, COUVE S, HASSANI Z et al.: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicenter study. Aliment. Pharmacol The]: (2003) 18:175–181.
   PubMed Web of Science ®Google Scholar
• SU C, SALZBERG BA, LEWIS JD et al: Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.Am.j Gastroenterol (2002) 97:2577–2584.
   PubMed Web of Science ®Google Scholar
• PROBERT CS, HEARING SD, SCHREIBER S et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomized controlledtrial. Gut (2003) 52:998–1002.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.Am. J. Gastroenterol (2003) 98:369–376.
   Google Scholar
• KANAUCHI 0, SERIZAWA I, ARAKI Y et al.: Germinated barley foodstuff, a prebiotic product, ameliorcates inflammation of colitis through modulation of the enteric environment. J. Gastroenterol(2003) 30:134–141.
   Google Scholar
• GIONCHETTI P, RIZZELLO F, HELWIG U et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double blind, placebo-controlled trial.Gastroenterology (2003) 124:1202–1209.
   PubMed Web of Science ®Google Scholar
• HART AL, STAGG AJ, KAMM MA: Use of probiotics in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol (2003) 36:111–119.
   PubMed Web of Science ®Google Scholar
• MANN S. Melatonin for ulcerative colitis. Am.j Gastroenterol (2003) 98:232–233.
   PubMedGoogle Scholar
• MOORE CB, SIOPES TD: Melatonin can produce immune enhancement in Japanese quail (Coturnix coturnix japonica) without prior immunosuppression. Gen. Comp. Endocrinol (2002) 129:122–126.
   PubMedGoogle Scholar
• VERNIA P, ANNESE V, BRESCI G et al.: Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicenter trial. Ear: I Clin. Invest. (2003) 33:244–248.
   Google Scholar
• SAWADA K, MUTO T, SHIMOYAMA T et al.: Multicenter, randomized controller trial for the treatment of ulcerative colitis with a leukocytopheresis column. Curl: Pharm. Des. (2003) 9:307–321.
   PubMed Web of Science ®Google Scholar